AKT1 and prostate carcinoma: PC3 is a PTEN-negative prostate carcinoma cell line with constitutive activation of the PI3K-Akt ﻿pathway.﻿ LNCaP is an androgen receptor-positive and androgen-dependent growing prostate carcinoma cell line.